T he National Committee for Quality Assurance (NCQA) announced in May 2007 that it would discontinue the quality measure of beta-blocker use within 7 days of hospital discharge for myocardial infarction (MI). 1 The stated reasons for this decision were widespread achievement of nearmaximum use of beta-blockers in post-MI patients and little variance among health plans (and, therefore, little value as a quality measure to differentiate health plans). The NCQA 2006 report on the State of Health Care Quality showed that the use of beta-blockers after a heart attack was an average 94.3% of eligible patients in 2003, 96.2% in 2004, and 96.6% in 2005. 2 Data reported nearly 10 years earlier in the Healthcare Effectiveness Data and Information Set (HEDIS) Version 3.0 from NCQA's Quality Compass 1997 for quality-of-care data in 1996 showed average health plan performance at 62% of patients discharged after an MI, compared with 25% of patients in fee-for-service medicine. 3 The death of the quality measure of beta-blocker use after hospital discharge for MI marks an important success for managed health care.
As managed care celebrates this milestone, there are reports of interventions to increase the use of drug therapies for secondary prevention in patients discharged after acute MI. Daugherty et al. reported in March 2008 that post-MI patients who received early follow-up with a primary care physician (PCP) or cardiologist within 1 month of discharge were more likely to be prescribed beta-blockers at 6 months of follow-up, 80.1% compared with 71.3% of post-MI patients who did not receive early outpatient follow-up (P = 0.001). 4 In a coincident article, Smith et al. found that 2 early follow-up mailings 2 months apart to 836 patients who had been dispensed beta-blockers after acute MI significantly improved adherence to beta-blockers. 5 Over the 9 months of follow-up after the first mailing in 4 health maintenance organizations in Boston, Minneapolis, Atlanta, and Portland, the patients who received the mail intervention were 17% more likely (relative risk, 1.17; 95% [confidence interval], 1.02-1.29) to have received beta-blockers to cover 80% of the days in the follow-up period.
In this issue of JMCP, Lee et al. found that only 63.9% of patients with hospital claims for acute coronary syndrome (ACS, including unstable angina as well as acute MI), received beta-blockers within 3 months of hospital discharge. 6 This report by Lee et al. from a large managed care plan and the reports 1 month earlier about interventions to improve beta-blocker utilization in post-MI patients appears to be at odds with the decision by NCQA to discontinue this quality measure. What is going on here?
The principal answer to the question involves an interesting sojourn into the world of quality measurement. In the HEDIS quality measure of beta-blocker use after acute MI, the denominator is narrowed to include only patients discharged after MI with "no evidence of contraindication." Contraindication to betablockers is defined broadly in the HEDIS measure to exclude acute MI patients with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for insulin-dependent diabetes mellitus, asthma, heart block greater than first degree, sinus bradycardia, congestive heart failure, left ventricular dysfunction, or chronic obstructive pulmonary disease. 7 The research by Lee et al. made none of these exclusions, making their denominator much larger and, therefore, their result (63.9%) much smaller than the HEDIS average (94%-96%) during this time period. Lee et al. listed additional limitations that may have contributed to an underestimate of appropriate beta-blocker use in ACS patients, including inability to measure medication use not recorded in pharmacy claims (e.g., drugs dispensed as physician samples or during rehospitalization).
The current research performed by Daugherty et al. and Smith et al. highlight the difference between ostensible quality measures and real-world medical care. Daugherty et al. investigated the use of 4 categories of secondary prevention at 6 months after acute MI, underscoring the continued real-world interest in the use of evidence-based preventive therapies 6 months or more removed from the acute event that defined ACS. 4 Smith et al. addressed a similar but more narrow objective, the use of beta-blockers at 9 months of follow-up after hospital discharge for acute MI. 5 In Smith et al. and Lee et al., the health plans involved in the research quite likely participate in HEDIS reporting.
So, perhaps the death of 1 quality measure is really a prelude to the birth of an equally important quality measure, the proportion of health plan members that remain on therapy for secondary prophylaxis of ACS at 6 or 12 months after the acute event that defined ACS. Unfortunately, the research reported by Lee et al. does nothing to advance our knowledge of the use of beta-blockers at specific points in time after the index hospitalization for ACS. In addition to the many limitations acknowledged by Lee et al., including the absence of assessment of rehospitalizations in the 18-month follow-up period, this research measured only the receipt of 1 or more dispensings of each of the 3 target drug categories at any time over the 18-month follow-up period. 6 As for other secondary prevention therapies, Lee et al. found seemingly low use (51.8%) of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, at least 1 dispensing during the 3 months post discharge for ACS patients. For statins, 62.6% of patients received 1 more dispensing of this secondary preventive therapy during the 3 months post-ACS discharge. And, there was a low proportion of ACS patients (29.9%) that received at least 1 dispensing of all 3 secondary prevention therapies during the first 3 months of follow-up after the index hospital discharge with an ACS diagnosis.
Compared with the 69.3% of post-ACS discharge patients who received at least 1 dispensing of a statin during the first 6 months of follow-up in the study by Lee et al., Ye et al. found that less than 50% of patients with a diagnosis for coronary heart disease (CHD) received outpatient statin therapy within 6 months of discharge. With the demise of the HEDIS measure of beta-blocker use after hospitalization for acute MI, the stage seems to be set for new measures of health care quality in secondary prevention of cardiovascular events. Daugherty et al. point us to some benchmarks for possible quality measures in acute-MI patients after discharge, following intervention with a PCP or cardiologist: 80.1% receiving beta-blockers at 6 months, 82.9% for aspirin, and 75.9% for statins. 4 Unfortunately, the research reported by Lee et al. in this issue of JMCP does not address this evolving quality measure but does remind us of the importance of specifying the type of ACS patient when assessing the relative quality of care among managed care organizations. The report card presented by Lee et al. gives an inflated "grade" for the proportion of ACS patients who received beta-blockers (69.2%) and statins (69.3%) at any time over 6 months of follow-up but does so without consideration of individual patient characteristics and no exclusions for contraindications or intolerance with these therapies, factors that would cause the reported grade to be higher if included in the calculation of the quality measure.
